1st Quarter - Report

W STRATEGIES, LLC for GILEAD SCIENCES, INC.

Period 1st Quarter 2020 Filed Apr 20, 2020 Signed by Darren Willcox

Official filing
Firm
W STRATEGIES, LLC
Client
GILEAD SCIENCES, INC.
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Regulatory and legislative proposals in the Administration's Drug Pricing Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: Executive Office of the President (EOP); Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3 (116th), S. 2543 (116th), H.R. 19 (116th)

Health Issues HCR

Issues related to potential therapies for COVID-19.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Office of the Vice President of the United States

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.